Get To Know Us

Michael Triplett, Ph.D.

Michael Triplett, Ph.D.

Co-founder & Board Member

Michael Triplett, Ph.D. is an accomplished entrepreneur and veteran start-up executive. Dr. Triplett is passionate about translating world-class science and technology into transformative businesses, products, and capabilities that enhance human health, American competitiveness, and economic opportunity. Prior to Clarametyx, Dr. Triplett co-founded and served as President and CEO of Myonexus Therapeutics, a clinical stage gene therapy company developing first-ever treatments for limb-girdle muscular dystrophies, which was acquired by Sarepta Therapeutics in April 2019. He is prior CEO of N8 Medical, Inc., and previously held leadership roles spanning business development, innovation, new ventures, and strategy for the Health & Life Sciences Global Business at Battelle. He received his bachelor’s degree and Ph.D., both in Chemical Engineering, from The Ohio State University.

Close

Clarametyx Expanded Access Policy

Clarametyx Biosciences is a clinical stage biopharmaceutical company committed to developing novel immune-enabling therapies for serious or difficult-to-treat respiratory diseases.

“Expanded access” refers to use of an investigational drug outside of a clinical trial, where the use of the drug is for treatment, rather than gathering data in support of a marketing application.

The main goal of ongoing clinical trials for our investigational agent, CMTX-101, is to gain information about the drug’s safety and efficacy to submit an application to Health Authorities in support of approval to market CMTX-101. For this reason, Clarametyx believes that direct enrollment in a clinical trial is the preferred route of access to a drug, for which we are continuing to develop data on safety, efficacy and tolerability. We believe expanded access outside of a clinical trial may interfere with the conduct of ongoing trials and may disrupt the progress of our development programs, which could potentially delay access to other patients in need.

For this reason, Clarametyx is not making its investigational drugs available on an expanded access basis at the present time. We plan to re-evaluate this policy in the future as additional information becomes available from ongoing clinical trials.

If you have any questions about this policy or would like information about how to participate in our clinical studies, please contact us at info@clarametyx.com. More information on our ongoing clinical trial is available at ClinicalTrials.gov (http://www.clinicaltrials.gov, NCT06159725).

As authorized by the 21st Century Cures Act, Clarametyx may revise this expanded access policy at any time.